Previous close | 2.1500 |
Open | 2.3500 |
Bid | 1.8000 |
Ask | 2.1400 |
Strike | 125.00 |
Expiry date | 2025-01-17 |
Day's range | 1.7700 - 2.3500 |
Contract range | N/A |
Volume | |
Open interest | 2.03k |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.